DEA decision on Cannabis aligns with Kannalife’s focus

For over 6 years now, Kannalife Sciences has taken a scientific “by the book” approach meeting the strict DEA and FDA criteria to researching and developing cannabinoids. We have spent time understanding the cannabinoids safety & efficacy profiles to deliver the best available pharmaceutical medicine.

We commend the DEA and respect their position as the “FDA drug approval process is the most appropriate way to assess whether a product derived from marijuana or its constituents is safe and effective and has an accepted medical use.”

See below the letter from the DEA in response to the petition (courtesy of NPR):